ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,222.68
0.16%
US Tech 100
17,659.20
0.10%
Dow Jones
39,512.84
0.32%
Brent Oil
82.585
-1.63%
Bitcoin
60,697.85
-3.73%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Acticor Biotech (ALACT) Quote

Acticor Biotech

Acticor Biotech (ALACT)

EU
0.802
0.046
(6.08%)
Closed May 10 11:30AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
0.802
Bid
0.80
Ask
0.83
Volume
247,643
0.646 Day's Range 0.85
0.27 52 Week Range 6.20
Market Cap
10.551M
Previous Close
0.756
Open
0.646
Last Trade
824
@
0.802
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
96,304
Shares Outstanding
13,189,141
Dividend Yield
-
PE Ratio
-0.66
Earnings Per Share (EPS)
-1.2
Revenue
2.7M
Net Profit
-15.88M

About Acticor Biotech

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.acticor-biotech.com
Headquarters
Paris, Paris, Fra
Founded
1970
Acticor Biotech is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ALACT. The last closing price for Acticor Biotech was 0.76 €. Over the last year, Acticor Biotech shares have traded in a share price range of 0.27 € to 6.20 €.

Acticor Biotech currently has 13,189,141 shares outstanding. The market capitalization of Acticor Biotech is 10.55 € million. Acticor Biotech has a price to earnings ratio (PE ratio) of -0.66.

ALACT Latest News

More News

ACTICOR BIOTECH: Postponement of the Publication of Annual Results and Universal Registration Document 2023

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of glenzocimab, an innovative drug for the treatment of cardiovascular...

April 30 2024
Business Wire

ACTICOR BIOTECH : Résultats principaux de l’étude de phase 2/3 ACTISAVE dans le traitement de l’AVC

L’analyse du critère principal et du critère secondaire de l’étude de phase 2/3 ACTISAVE ne montre pas d’efficacité du glenzocimab Les principales données de cette étude seront présentées à...

April 25 2024
Business Wire

Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024

Results of ACTISAVE phase 2/3 clinical study in stroke expected in Q2 2024 Presentation of results during ESOC from 15 to 17 May 2024 Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 –...

April 15 2024
Business Wire

ACTICOR BIOTECH: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 mars 2024

Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT) (Paris:ALACT), société biopharmaceutique au stade clinique...

April 05 2024
Business Wire

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of February 29, 2024

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular...

March 18 2024
Business Wire

Acticor Biotech réalise avec succès une augmentation de capital d’un montant total de 8 millions d'euros

Regulatory News: Ne pas diffuser, publier ou distribuer, directement ou indirectement, aux Etats-Unis d'Amérique, au Canada, en Australie ou au Japon. Ce communiqué de presse ne constitue pas un...

March 15 2024
Business Wire

Acticor Biotech lance une augmentation de capital de 7 M€ au minimum

Augmentation de capital composée d’une offre à des investisseurs qualifiés, à des catégories d’investisseurs, ainsi qu’aux investisseurs individuels via la plateforme PrimaryBid Engagements de...

March 14 2024
Business Wire

The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack

University of Birmingham and Acticor Biotech News ReleaseLimited clinical access available The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first...

February 07 2024
GlobeNewswire Inc.

L'Université de Birmingham et Acticor Biotech annoncent le traitement du premier patient dans l'étude clinique LIBERATE

LIBERATE, première étude clinique évaluant le glenzocimab dans le traitement de l'infarctus du myocarde Regulatory News: L'Université de Birmingham et Acticor Biotech (Paris:ALACT) sont fiers...

February 07 2024
Business Wire

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke    438 patients with stroke have been randomized in ACTISAVE study evaluating glenzocimab, in...

November 07 2023
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.413106.169665810.3890.9340.382305160.6971193DE
4-2.838-77.9670329673.644.210.272361400.5568706DE
12-3.398-80.90476190484.25.30.27963041.05986496DE
26-2.998-78.89473684213.85.320.27499731.40079347DE
52-5.298-86.85245901646.16.20.27253871.51906868DE
156-0.658-45.06849315071.46110.27295132.66146863DE
2600.6297.029702970.202110.11661941.17699184DE

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TVGNTevogen Bio Holdings Inc
$ 1.34
(36.11%)
772.2k
NXUNXU Inc
$ 0.4899
(19.08%)
2M
ATRAAtara Biotherapeutics Inc
$ 0.6021
(13.63%)
7.96k
WAVDWaveDancer Inc
$ 3.37
(13.09%)
37.26k
MIGIMawson Infrastructure Group Inc
$ 1.15
(12.75%)
27.37k
AEHLAntelope Enterprise Holdings Ltd
$ 1.58
(-17.28%)
62.08k
BMRABiomerica Inc
$ 0.52
(-11.58%)
4.06k
RNAZTransCode Therapeutics Inc
$ 1.26
(-10.64%)
131.25k
AUVIApplied UV Inc
$ 0.55
(-10.35%)
720.52k
ALBTAvalon GloboCare Corporation
$ 0.31
(-8.82%)
229.51k
GWAVGreenwave Technology Solutions Inc
$ 0.0439
(0.00%)
4.99M
FFIEFaraday Future Intelligent Electric Inc
$ 0.0438
(-4.99%)
2.91M
NVAXNovavax Inc
$ 8.90
(0.23%)
2.89M
HSTHost Hotels and Resorts Inc
$ 18.34
(0.00%)
2.81M
LIDRAEye Inc
$ 2.44
(-5.43%)
2.73M

Discussion

View Full Feed
pos_stock_hoarder pos_stock_hoarder 3 minutes ago
LMBO!
GoodGuyBill GoodGuyBill 4 minutes ago
MAA Application. As previously reported, the Company filed a Marketing Authorization Application (MAA) to the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) on December 20, 2023, seeking regulatory approval for commercialization of DCVax - L for newly diagnosed and recurrent Gliobla
NWBO
JERSEYHAWG JERSEYHAWG 4 minutes ago
they did this before....



Lehman Brothers Holdings Inc.

12

 0

January 6, 2022, Southern District of New York – Varde Investment Partners, L.P. transfers its claims in the face amount of $8,395,690.46 (Claim No. 27940) to Sea
LEHNQ
dennisdave dennisdave 4 minutes ago
I heard otherwise. But I hope you are right ofcourse. Anyway in that case 70 days from March 7 is May 17th or about.
Lets hope so
NWBO
JAB65 JAB65 4 minutes ago
Now that is truly cool information and there's no reason to doubt what you say isn't true. Both sides were doing some pretty amazing things during those years technologically speaking.

We went from the Wright brothers to jets in such a short period of time. It still blows my mind, wh
TGLO
pos_stock_hoarder pos_stock_hoarder 5 minutes ago
No argument here!
12BeRich 12BeRich 5 minutes ago
Friendly reminder that Dshade has stated himself, he has no “inside information” and his statements are just guesses. He also stated the company was done raising funds by selling shares at a discount…which fins prove otherwise. So he is wrong or a liar, you pick.

5/12/21 the share pr
ECSL
JMMatthews JMMatthews 5 minutes ago
You think a $600 buy is a paint job, when a $6 slap could have accomplished the same result? 🤣

https://ih.advfn.com/stock-market/USOTC/digital-brand-media-and-pk-DBMM/trades

DBOOMM $$$
DBMM
MightyX MightyX 6 minutes ago
VuMe SuperAPP(1st western hemisphere SuperApp)worth Billions/wait..imo
TPTW
Saving Grace Saving Grace 7 minutes ago
ERBB Boom! Coming soon enough. Why are some in a full panic over the CBD gummies now on Amazon? It's frightening.

https://external-content.duckduckgo.com/iu/?u=https%3A%2F%2Fwww.swagshirts99.com%2Fwp-content%2Fuploads%2F2017%2F01%2FIMG_2986.jpg&f=1&nofb=1&ipt=57b30d4992841cf1bf400b7cf
ERBB
norisknorewards norisknorewards 7 minutes ago
how much are you buying Monday?
NWBO
toncatmad toncatmad 8 minutes ago
What does it being delisted in 11/19 have to do with anything? LCY even if they go public Monday it won’t change anything for those worthless shares lol
peafunke peafunke 8 minutes ago
I think they couldn’t offer value yet. Vume needs traction and users before it can claim $5 series e shares.

I think they will try to grow organically near term. But no Nasdaq anytime soon.
TPTW
MightyX MightyX 8 minutes ago
Shame it had to be that way..something bigger then…new acquisitions coming. Very interesting turn of events..we know TPT has what big tech has been trying to accomplish so good things..it just wasn’t with TekMovil.
TPTW
exwannabe exwannabe 9 minutes ago
Riddle me this bear.

NWBO is still preparing for inspections. What do you think a timeframe is for those inspections (across 2 continents) to happen? How long to evaluate the results and put together a formal analysis?
NWBO
TTsr TTsr 9 minutes ago
But you know what this means?? When the big boys start buyin there’s gonna be a huuuuge bump up in SP.

IT.
IS.
ONLY.
A.
MATTER.
OF.
TIME.

Sorry, getting arts-n-fartsy after a few wines! Got an early start here on the East Co
NWBO
mc73 mc73 9 minutes ago
I would think we are at minimum 2-3 years away from uplisting. Will be a great ride - I'm confident we get there unless 1 of 2 things happen:

1. We don't get IDE (doubt this happens)

2. Big pharma buys the company

The future is brighter than ever, for lo
RDGL
Red_Right_Hand Red_Right_Hand 9 minutes ago
There is no 60-day clock off if there's no RFI. The 60-day clock off is up-to-60 days for applicant to answer the RFI. If no RFI, then no clock-off.
The assessment runs in two phases totalling 150 days with a 60-day clock off period between phases if needed. https://uk.practicallaw.thomsonre
NWBO
Jackxkr Jackxkr 9 minutes ago
That filing was basically nothing, sorry to bring reality back.
It was neither very good or very bad.
NWBO
NASDAQ2020 NASDAQ2020 9 minutes ago
With all those goats no need for heating the shack
ELTP
toogoodfella toogoodfella 10 minutes ago
Amount of Claim: $122,834,000.00

SOLD TO;

STONEHILL INSTITUTIONAL PARTNERS LP
320 PARK AVENUE, 26TH FLOOR
NEW YORK NY 10022

NEW YORK NY
Hedge Fund
Stonehill Institutional Partners is based out of New York. Whalewisdom ha
LEHNQ
Backstabbed Backstabbed 11 minutes ago
Seriously? You think $0.01 is feasible here?
TPTW

Your Recent History

EU
ALACT
Acticor Biotech
LSE
BG.
BG Group
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved